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OBJECTIVE—We previously showed that elevating hepatic
nitric oxide (NO) levels reduced net hepatic glucose uptake
(NHGU) in the presence of portal glucose delivery, hyperglyce-
mia, and hyperinsulinemia. The aim of the present study was to
determine the role of a downstream signal, soluble guanylate
cyclase (sGC), in the regulation of NHGU by NO.
RESEARCH DESIGN AND METHODS—Studies were per-
formed on 42-h–fasted conscious dogs ﬁtted with vascular cath-
eters. At 0 min, somatostatin was given peripherally along with
4 basal insulin and basal glucagon intraportally. Glucose was
delivered at a variable rate via a leg vein to double the blood
glucose level and hepatic glucose load throughout the study.
From 90 to 270 min, an intraportal infusion of the sGC inhibitor
1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one (ODQ) was given in
sGC (n  10) and sGC/NO (n  6), whereas saline was
given in saline infusion (SAL) (n  10). The sGC/NO group
also received intraportal SIN-1 (NO donor) to elevate hepatic NO
from 180 to 270 min.
RESULTS—In the presence of 4 basal insulin, basal glucagon,
and hyperglycemia (2 basal ), inhibition of sGC in the liver
enhanced NHGU (mg/kg/min; 210–270 min) by 55% (2.9  0.2
in SAL vs. 4.6  0.5 in sGC). Further elevating hepatic NO failed
to reduce NHGU (4.5  0.7 in sGC/NO). Net hepatic carbon
retention (i.e., glycogen synthesis; mg glucose equivalents/kg/
min) increased to 3.8  0.2 in sGC and 3.8  0.4 in sGC/NO
vs. 2.4  0.2 in SAL (P  0.05).
CONCLUSIONS—NO regulates liver glucose uptake through a
sGC-dependent pathway. The latter could be a target for phar-
macologic intervention to increase meal-associated hepatic glu-
cose uptake in individuals with type 2 diabetes. Diabetes 59:
2999–3007, 2010
N
et hepatic glucose uptake (NHGU) has been
shown to be regulated by a number of factors,
including the glucose load to the liver, the
hepatic sinusoidal insulin level, and the nega-
tive glucose gradient between the hepatic artery and
hepatic portal vein (1). When comparing the effects of
peripheral versus portal venous glucose delivery on NHGU
under hyperinsulinemic hyperglycemic conditions in dogs,
NHGU was found to be considerably greater in the pres-
ence of intraportal glucose delivery, even when the he-
patic glucose loads were well matched and insulin and
glucagon levels were equivalent between groups (2–4).
This suggested that a “portal glucose signal” is an impor-
tant determinant of NHGU after an oral glucose load. To
date, it remains unclear how the response to portal
glucose delivery comes about.
In an earlier study we showed that portal but not
peripheral infusion of a nitric oxide (NO) donor 3-morpho-
lino-sydnonimine (SIN-1) reduced NHGU in the presence
of portal glucose delivery, hyperglycemia, and hyperinsu-
linemia, suggesting that hepatic NO can regulate NHGU
through a direct effect on the liver (5). This ﬁnding raised
the possibility that NO may be involved in mediation of the
effect of the portal glucose signal. Such speculation is
supported by our ﬁnding that intraportal infusion of the
nitric oxide synthase (NOS) inhibitor L-NAME enhanced
NHGU under hyperinsulinemic hyperglycemic conditions
in vivo (6). Further, this augmentation was partially re-
versed by giving SIN-1 intraportally (6). In addition, we
recently found that the hepatic concentrations of nitrate
and nitrite, indexes of NO levels, declined in the postpran-
dial state in dogs (Z.A. et al., unpublished data), supporting
the possibility that NO is involved in the regulation of
NHGU.
The downstream consequences of NO action involve at
least two distinct pathways: cyclic guanosine monophos-
phate (cGMP)-dependent and cGMP-independent (7). The
cGMP-dependent effects result from the NO-induced acti-
vation of soluble guanylate cyclase (sGC), leading to
increased cGMP levels, which modulate the activity of
protein kinase G (PKG), cGMP-regulated phosphodiester-
ases (PDEs), and AMP-activated protein kinase (AMPK)
(7). The cGMP-independent effects include S-nitrosylation
and nitration of proteins (8). In addition, NO may couple
with reactive oxygen species to form reactive nitrogen
species such as peroxynitrite (7).
Despite the diversity of effects, it has been well docu-
mented that many metabolic actions of NO are mediated
by the activation of sGC and the subsequent increase in
the production of cGMP. A study in anesthetized cats
showed that bolus intraportal delivery of SIN-1 potentiated
norepinephrine-induced hepatic glucose output, and this
potentiation was blocked by inhibition of guanylate cy-
clase (9). It has also been shown that blockade of hepatic
NO production, or of its ability to activate guanylyl cy-
clase, impaired peripheral insulin sensitivity in anesthe-
tized rodents (10,11). However, no data are available
relating to the effects of sGC on hepatic glucose uptake
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that a sGC-dependent mechanism is involved in the re-
sponse of NHGU to hepatic NO, such that under hyperin-
sulinemic hyperglycemic conditions, blockade of sGC in
the liver increases NHGU and prevents the reduction of
NHGU caused by a rise in hepatic NO.
RESEARCH DESIGN AND METHODS
Animals and surgical procedures. Studies were performed on healthy
conscious 42-h–fasted mongrel dogs of either sex with a mean weight of
21.2  0.5 kg. A fast of this duration was chosen because it produces a
metabolic state resembling that in the overnight-fasted human and results in
liver glycogen levels in the dog that are at a stable minimum (2). All animals
were maintained on a diet of meat (Pedigree, Franklin, TN) and chow (Purina
Lab Canine Diet No. 5006; Purina Mills, St. Louis, MO) comprised of 34%
protein, 14.5% fat, 46% carbohydrate, and 5.5% ﬁber based on dry weight. The
animals were housed in a facility that met the American Association for
Accreditation of Laboratory Animal Care guidelines, and the protocol was
approved by the Vanderbilt University Medical Center Animal Care and Use
Committee.
Approximately 16 days before the study, each dog underwent a laparotomy
under general anesthesia (0.01 mg/kg buprenorphine before surgery, and 1%
isoﬂurane inhalation anesthetic during surgery), and silicone rubber sampling
catheters were inserted in the hepatic vein, the portal vein, and a femoral
artery as described elsewhere (2). Catheters for intraportal infusion were also
placed in a splenic and a jejunal vein, while ultrasonic ﬂow probes (Transonic
Systems, Ithaca, NY) were placed around the portal vein and the hepatic
artery as previously described (2).
Approximately 2 days before each study, blood was drawn to determine the
leukocyte count and the hematocrit for each animal. The dog was studied only
if it had a leukocyte count 18,000/mm
3, a hematocrit 35%, a good appetite
(as evidenced by consumption of 75% daily ration), and normal stools.
On the morning of the study, catheters and the ﬂow probe leads were
exteriorized from their subcutaneous pockets using local anesthesia (2%
lidocaine, Hospira, Lake Forest, IL). The contents of each catheter were
aspirated, and catheters were ﬂushed with saline. Angiocaths (Deseret Med-
ical, Becton Dickinson, Sandy, UT) were inserted into the cephalic veins and
the saphenous veins. Each dog was allowed to stand quietly in a Pavlov
harness throughout the experiment and was studied only once.
Experimental design. As described in Fig. 1A, each experiment consisted of
a 90-min equilibration period (120 to 30 min), a 30-min basal period (30
to 0 min), and a 270-min experimental period (0 to 270 min), with the latter
being divided into period one (P1), 0 to 90 min, and period two (P2), 90 to 270
min. In all experiments a constant infusion of indocyanine green dye (0.076
mg/min; Sigma Immunochemicals, St. Louis, MO) was initiated at 120 min
via the left cephalic vein. At the start of P1 (0 min), a constant infusion of
somatostatin (0.8 	g/kg/min; Bachem, Torrance, CA) was begun via the left
saphenous vein to suppress endogenous insulin and glucagon secretion. At the
same time, basal glucagon (0.57 ng/kg/min; Glucagen, Novo Nordisk, Bags-
vaerd, Denmark) and fourfold basal insulin (1.2 mU/kg/min; Eli Lilly & Co.,
Indianapolis, IN) infusions were started through the splenic and jejunal
catheters (i.e., intraportally) and maintained for the duration of the study. In
addition, at 0 min, a primed continuous infusion of 50% dextrose was started
via the right cephalic vein so that the blood glucose could be quickly clamped
at the desired hyperglycemic level (160 mg/dl). In P2, saline was infused
intraportally in the control group ([SAL], n  10), whereas the sGC inhibitor
1H- (1,2,4) oxadiazolo[4,3-a] quinoxalin-1-one (ODQ; Cayman Chemical Com-
pany, Ann Arbor, MI) was infused intraportally at 0.8 	g/kg/min to inhibit the
hepatic sGC pathway in the sGC (n  10) and sGC/NO (n  6) groups.
The NO donor SIN-1 (Cayman Chemical Company) was also infused intra-
portally (4 	g/kg/min) from 180 to 270 min in the sGC/NO group to elevate
hepatic NO levels. In a separate group (NO group; n  3), SIN-1 was infused
(4 	g/kg/min) from 90 to 270 min in the absence of ODQ. The peripheral
glucose infusion rate was adjusted as needed in P2 to maintain a similar
hepatic glucose load to that seen during P1.
After completion of each experiment, the animal was killed with an
overdose of pentobarbital and the abdomen was opened so that the positions
of the catheter tips could be veriﬁed. Liver samples were immediately
freeze-clamped with precooled Wallenburger tongs and stored at 70°C for
poststudy assays.
Processing and analysis of samples. The collection and immediate process-
ing of blood samples have been described previously (12). Four to eight 10-	l
aliquots of plasma from each sample were immediately analyzed for glucose
using the glucose oxidase technique in a glucose analyzer (Analox Instru-
ments, London, U.K.). Plasma insulin and glucagon concentrations were
determined by radioimmunoassay, as described elsewhere (13). Cortisol,
lactate, glycerol, and nonesteriﬁed fatty acid (NEFA) concentrations were
also measured as previously described (14). The concentrations of hepatic
cGMP were measured using a cGMP ELISA Kit (Cayman Chemical Company).
Electrophoretic separation, blotting, and immunodetection of proteins were
performed as described previously (15). Brieﬂy, tissue samples were homog-
enized in buffer including 50 mmol/l TrisHCl pH 7.0, 100 mmol/l sucrose, 10%
(vol/vol) glycerol, 2 mmol/l EDTA, 2 mmol/l EGTA, 25 mmol/l NaF, with
phosphatase and protease inhibitors (Sigma, St. Louis, MO). Homogenates
were centrifuged at 10,000 g for 30 min, and supernatants were removed,
mixed 1:1 (vol/vol) with 2X SDS-PAGE loading buffer (100 mmol/l TrisHCl, pH
6.8, 4% [wt/vol] SDS, 20% [vol/vol] glycerol, 0.2% [wt/vol] bromophenol blue,
10% [vol/vol] 2-mercaptoethanol), and boiled for 10 min. Samples were then
subjected to SDS-PAGE (4–12% resolving gel) followed by transfer to nitro-
cellulose membranes. Membranes were incubated with the appropriate pri-
mary antibody (Cell Signaling, Danvers, MA), followed by horseradish
peroxidase (HRP)-conjugated secondary antibody (Promega, Madison, WI).
Proteins were visualized with ECL Plus Western blotting detection reagents
(GE Healthcare, Piscataway, NJ) and the ECL signal was detected after brief
exposure to X-ray ﬁlm. Bands were quantiﬁed with ImageJ software (http://
rsb.info.nih.gov/ij). Hepatic phosphodiesterase 3 activity was determined
using a modiﬁcation of the phosphodiesterase assay described by Loten et al.
(16), and enzyme activity (pmol
3H cAMP hydrolyzed) was calculated by
radioactivity counts (cpm) times 0.0000326 pmol/cpm, and normalized by
protein dry weight (mg). The activities of hepatic glycogen synthase and
phosphorylase were measured as described elsewhere (17,18).
Calculations and data analysis. Hepatic blood ﬂow ([HBF] ml/kg/min) was
measured using ultrasonic ﬂow probes and by the use of indocyanine green
dye according to the method of Leevy et al. (19). The results obtained with the
ﬂow probes and dye were not signiﬁcantly different, but the data reported here
were calculated using the former because their measurement did not require
an assumption regarding the distribution of the arterial and portal vein
contribution to HBF.
Net hepatic glucose balance (NHGB; mg/kg/min) was calculated as:
NHGB  Loadout  Loadin.
Loadin  (GAABF)  (GPPBF).
Where GA (mg/ml) is the arterial blood glucose concentration, GP (mg/ml)
is the portal blood glucose concentration, ABF (ml/kg/min) is hepatic arterial
blood ﬂow, and PBF (ml/kg/min) is hepatic portal blood ﬂow.
The load of glucose exiting the liver was calculated as:
Loadout  (GH  HBF).
Where GH (mg/ml) represents the hepatic vein glucose concentration and
HBF  ABF  PBF.
The average nonhepatic glucose uptake between two time points (T1 and
T2) was calculated by subtracting the rate of NHGU and the change in the
glucose mass from the total glucose infusion rate using the equation:
nonhepatic glucose uptake rate  average total glucose infusion rate between
T1 and T2  (NHGUT1  NHGUT2)/2  the change in the glucose mass
between T1 and T2. In a previous study, we were able to determine that under
hyperinsulinemic and hyperglycemic conditions, virtually all the increase in
nonhepatic glucose uptake could be accounted for muscle glucose uptake
(12). Net hepatic carbon retention was calculated as the sum of the net
balances of glucose and lactate once the latter was converted to glucose
equivalents (5). The calculation of net hepatic carbon retention is an estab-
lished approach to estimate hepatic glycogen accretion and has been de-
scribed and validated previously (20). Although the calculation omits the
contribution of gluconeogenic substrates other than lactate and fails to
account for glucose oxidized by the liver, these two rates are quantitatively
similar and offsetting. Net hepatic fractional glucose extraction was calculated
as the ratio of NHGB to Loadin. The net hepatic balances of lactate, glycerol,
and NEFA were calculated as for glucose. The hepatic sinusoidal insulin and
glucagon concentrations were calculated as described elsewhere (21).
For all glucose balance calculations, glucose concentrations were con-
verted from plasma to blood values by using previously determined (22,23)
conversion factors (CF: the mean of the ratio of the blood value to the plasma
concentration). The use of whole blood glucose values ensures accurate
hepatic balance measurements regardless of the characteristics of glucose
entry into the erythrocyte.
Statistical analysis. All data are presented as means  SEM. Time course
data were analyzed with two-way repeated measures ANOVA, and one-way
ANOVA was used for comparisons of other mean data. Post hoc analysis was
performed using the Student-Newman-Keuls method. Statistical signiﬁcance
was accepted at P  0.05.
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Inhibition of cGMP levels in the liver. To verify the
inhibition of sGC in the liver, hepatic cGMP levels were
measured in biopsies taken at the end of the experiments.
Relative to saline infusion (SAL), intraportal infusion of
the sGC inhibitor ODQ (sGC) led to a decrease of 26% in
hepatic cGMP levels, (Fig. 1B) whereas SIN-1 alone (NO)
increased cGMP levels in the liver by 31%. ODQ effectively
blocked the ability of the NO donor to elevate cGMP
levels.
Hormone concentrations. During the hyperinsulinemic
hyperglycemic clamp (P1 and P2), the arterial and hepatic
sinusoidal insulin levels quickly increased three to four-
fold and remained stable thereafter (Table 1). Arterial and
hepatic sinusoidal plasma glucagon concentrations, on the
other hand, remained basal throughout the study in all
groups, as did the arterial plasma cortisol concentrations
(Table 1).
Hepatic blood ﬂow, blood glucose concentrations,
and hepatic glucose load. Portal vein blood ﬂow
decreased 20% in all groups in response to somatosta-
tin infusion (Table 2). There was a concomitant and
partly offsetting (10–20%) increase in hepatic arterial
ﬂow. Consequently, total hepatic blood ﬂow tended
to be reduced slightly (10%) during the experi-
mental period, but it was unaffected by ODQ or SIN-1
infusion.
During the hyperglycemic clamp, arterial blood glucose
levels increased in all the groups from a basal value of 80
to 160 mg/dl (Fig. 2A, Table 3). The hepatic glucose loads
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FIG. 1. Schematic representation of the study (A) and hepatic cGMP levels (B). The protocol comprises the basal (30 to 0 min) and experimental
periods (period 1: 0–90 min; period 2: 90–270 min). Somatostatin was infused peripherally and insulin (fourfold basal) and glucagon (basal) were
given intraportally, whereas glucose was delivered peripherally at a variable rate to increase the hepatic glucose load twofold basal during period
1 and period 2. Data are means  SEM. *P < 0.05 compared with the SAL group. †P < 0.05 compared with the NO group.
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(Fig. 2B, Table 3).
Net hepatic glucose balance and net hepatic frac-
tional glucose extraction. All groups exhibited a similar
rate of net hepatic glucose output during the basal period.
Coincident with the start of the experimental period (4
basal insulin, basal glucagon, and hyperglycemia), all
groups switched from net output to net uptake of glucose,
and the rates (2.3  0.3, 2.2  0.3, and 2.5  0.4 mg/kg/min
in SAL, sGC, and sGC/NO, respectively) did not differ
among the groups (Fig. 2C). During the last hour of the
experiment, NHGU was 2.9  0.2 mg/kg/min in SAL and
4.6  0.5 and 4.5  0.7 mg/kg/min (P  0.05 vs. SAL) in
sGC and sGC/NO, respectively. The net hepatic
fractional extraction of glucose followed a similar pattern,
increasing similarly in response to the inhibition of sGC,
even when the NO donor, SIN-1, was present (Fig. 2D).
Infusing SIN-1 in the absence of ODQ (NO; Table 3) had
no effect on NHGU (2.8  0.8 mg/kg/min during the last
hour of the experiment; Table 3). Taken together, the
above data suggest that a decrease in hepatic cGMP brings
about an increase in NHGU. Further, since SIN-1 could not
reduce NHGU when hepatic sGC was inhibited, it appears
that NO brings about its effect through this mechanism.
Glucose infusion rates and nonhepatic glucose up-
take. The glucose infusion and nonhepatic glucose uptake
rates increased over time in all groups (Fig. 2E, Table 3).
In the sGC and sGC/NO groups, the glucose infusion
rates were signiﬁcantly increased over that required in the
saline and NO group. Nonhepatic glucose uptake did not
differ signiﬁcantly between groups at any time, although
there was a tendency for it to be increased in the presence
of ODQ (Fig. 2F, Table 3).
Lactate metabolism and net hepatic carbon reten-
tion. The arterial blood lactate concentrations rose in all
groups during P1 and P2 (Table 4). After the experimental
period began, net hepatic lactate balance changed from
uptake to output, and this continued in all groups during
P2 (Table 4). An index of hepatic glycogen accretion, net
hepatic carbon retention (mg glucose equivalents/kg/min),
did not differ among groups during P1 (1.8  0.3, 1.4  0.6,
1.9  0.3, and 1.8  0.2 in SAL, NO, sGC, and
sGC/NO. respectively) but was increased (P  0.05)
relative to the SAL and NO group during P2 in response
to sGC inhibition, regardless of the presence or absence of
SIN-1 (2.4  0.2 in SAL, 2.3  0.5 in NO vs. 3.8  0.2 in
sGC and 3.8  0.4 in sGC/NO).
Glycerol and nonesteriﬁed fatty acid metabolism.
Arterial blood glycerol concentrations and net hepatic
glycerol uptake were reduced by 55 to 70% in response to
hyperinsulinemia and remained suppressed in all groups
during P1 (Table 4). The suppression of glycerol was,
however, partially reversed during P2 in the NO but not
SAL, sGC, and sGC /NO groups (Table 4). This is
TABLE 1
Average hormone concentrations during the basal and experi-
mental periods in conscious 42-h–fasted dogs given saline, ODQ,
ODQ  SIN-1, or SIN-1 into the portal vein
Experimental period
Group
Basal
period Period 1 Period 2
Arterial plasma
insulin, 	U/ml
SAL 8  12 0  2* 23  2*
sGC 7  12 0  2* 22  2*
sGC/NO 6  11 8  2* 21  2*
NO 7  21 8  1* 21  2*
Hepatic sinusoidal
insulin, 	U/ml
SAL 23  38 5  12* 83  8*
sGC 24  58 0  8* 85  10*
sGC/NO 19  38 9  8* 83  6*
NO 25  38 8  20* 82  9*
Arterial plasma
glucagon, pg/ml
SAL 39  43 9  33 6  4
sGC 41  44 0  43 8  3
sGC/NO 33  43 5  43 5  3
NO 43  24 6  12 43  9
Hepatic sinusoidal
glucagon, pg/ml
SAL 44  65 2  44 9  5
sGC 47  75 3  65 4  5
sGC/NO 40  65 0  34 7  3
NO 47  36 1  75 6  8
Arterial cortisol,
	g/dl
SAL 4  14  13  1
sGC 4  14  12  1
sGC/NO 4  13  13  1
NO 6  44  24  2
Data are means  SEM; n  10 in SAL and sGC groups. n  6i n
the sGC/NO group. n  3i nt h e NO group. *Signiﬁcant
statistical difference (P  0.05) from basal period within the group.
Basal period: 30 to 0 min; experimental period 1: 0–90 min; period
2: 90–270 min.
TABLE 2
Average hepatic arterial, portal, and total hepatic blood ﬂow
during the basal and experimental periods in conscious 42-h–
fasted dogs given saline, ODQ, ODQ  SIN-1, or SIN-1 into the
portal vein
Experimental period
Group
Basal
period Period 1 Period 2
Average hepatic
arterial blood ﬂow,
ml/kg/min
SAL 5.4  0.4 6.4  0.5 7.3  0.8*
sGC 6.1  0.8 7.8  1.1 8.6  1.0*
sGC/NO 5.0  0.4 5.0  0.4 5.7  0.4
NO 4.7  1.3 4.3  0.6 5.2  0.8
Average hepatic portal
blood ﬂow,
ml/kg/min
SAL 24.1  2.0 19.4  1.9* 18.4  1.8*
sGC 26.4  2.4 20.0  2.2* 20.1  2.0*
sGC/NO 23.3  3.2 18.3  2.2 19.5  2.3
NO 21.5  4.3 17.2  4.1 20.3  3.1
Average total hepatic
blood ﬂow,
ml/kg/min
SAL 29.5  2.1 25.8  2.1 25.7  2.1
sGC 32.5  2.8 27.7  3.0 28.7  2.6
sGC/NO 28.3  3.5 23.3  2.4 25.2  2.5
NO 26.2  3.9 21.5  3.5 25.5  2.3
Data are means  SEM; n  10 in SAL and sGC groups. n  6i n
the sGC/NO group. n  3i nt h e NO group. *Signiﬁcant
statistical difference (P  0.05) from basal period within the group.
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SIN-1 resulted in a rebound of lipolysis under hyperinsu-
linemic hyperglycemic conditions (5). This effect was
blocked in the present study when ODQ was given at the
same time. Arterial plasma NEFA concentrations and net
hepatic NEFA uptake changed in a pattern similar to
glycerol (Table 4).
Glycogen metabolism and insulin signaling in the
liver. In agreement with net hepatic carbon retention
data, the hepatic glycogen content at the end of the
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FIG. 2. Arterial blood glucose (A), hepatic glucose loads (B), net hepatic glucose uptake (C), net hepatic fractional extraction of glucose (D),
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greater following the inhibition of sGC (SAL vs. sGC;
Table 5). However, hepatic glycogen synthase and phos-
phorylase activities were not different between the two
groups (Table 5). Phosphorylation of hepatic AKT and
GSK-3 
 in the liver also did not differ between the two
groups (Table 5).
AMP-activated protein kinase signaling and phospho-
diesterase 3 activity in the liver. Compared with the
saline group, intraportal infusion of ODQ was associated
with a decrease of 30% in the phosphorylation of phos-
pho-AMPK (Thr172) in the liver as well in the phosphor-
ylation of Ser-79 in its downstream target acetyl-CoA
carboxylase (ACC) (Fig. 3). In contrast, intraportal SIN-1
alone, which elevated hepatic NO, was associated with a
25% increase in phospho AMPK and a 30% increase in
phospho ACC (Fig. 3). ODQ blocked the effect of the NO
donor SIN-1 on the phosphorylation of both AMPK and
ACC. PDE3 (cGMP-inhibited cAMP phosphodiesterase)
activity (pmol/min/mg dry weight) was not altered by
inhibition of hepatic sGC (3.6  10
3  0.3  10
3 in ODQ
vs. 3.2  10
3  0.3  10
3 in SAL).
DISCUSSION
To our knowledge, this is the ﬁrst in vivo work that
assessed the effects of the sGC pathway on glucose uptake
by the liver under hyperinsulinemic hyperglycemic condi-
tions. Under these conditions, inhibition of sGC in the liver
caused an 50% increase in NHGU and hepatic glycogen
accumulation. Simultaneous elevation of hepatic NO was
not able to override the enhancement of NHGU induced by
sGC inhibition, suggesting that NO brings about its effect
through a sGC-dependent mechanism. Furthermore, the
correspondence between hepatic cGMP content and he-
patic AMPK activation raises the possibility that the latter
may be involved in the regulation of NHGU by this
pathway.
Our previous study showed that under hyperglycemic,
hyperinsulinemic conditions and in the presence of portal
glucose delivery, portal but not peripheral infusion of the
NO donor SIN-1 inhibited NHGU, suggesting that the effect
of NO was the result of a direct effect within the liver (5).
The three isoforms of NOS are expressed within the liver
(24–26), and NO infusion (0.15 	mol/g liver/min) has
been shown to activate glycogen breakdown in the per-
fused rat liver (27). Likewise, Sprangers et al. (28) showed
that glycogen synthesis in rat hepatocytes was inhibited by
the NO donor S-nitroso-N-acetylpenicillamine (SNAP).
The current study extends these earlier results by provid-
ing data to support the concept that sGC can regulate
NHGU in vivo under physiologic hyperinsulinemic, hyper-
glycemic conditions.
We chose ODQ as the tool to study the role of sGC in the
present study because it is considered to be the most
speciﬁc sGC inhibitor available (29). The cGMP data
clearly show that the drug hit its target. As with any
chemical blocker, however, one must consider whether it
might have caused a change through an off-target effect
(30). This seems unlikely in the present case for several
TABLE 3
Average arterial glucose, hepatic glucose load, total glucose
infusion rate, and nonhepatic glucose uptake during the basal
and experimental periods in conscious 42-h–fasted dogs given
SIN-1 (the NO group) into the portal vein
Experimental period
Parameters
Basal
period Period 1 Period 2
Arterial blood glucose, mg/dl 80  6 161  2* 159  4*
Hepatic glucose load,
mg/kg/min 19  23 4  6* 40  4*
Net hepatic glucose balance,
mg/kg/min 1.5  0.2 1.8  0.9* 2.8  0.8*
Total glucose infusion rate,
mg/kg/min 0 4.8  0.4 6.8  0.4
Nonhepatic glucose uptake,
mg/kg/min 1.5  0.2 3.4  0.7 4.4  0.9
Data are means  SEM; n  3. *Signiﬁcant statistical difference (P 
0.05) from basal period. Negative values for balance data indicate net
hepatic uptake.
TABLE 4
Average lactate, glycerol, and NEFA concentration and net
hepatic balance during the basal and experimental periods in
conscious 42-h–fasted dogs given saline, ODQ, ODQ  SIN-1, or
SIN-1 into the portal vein
Experimental period
Group
Basal
period Period 1 Period 2
Arterial blood lactate,
	mol/l
SAL 506  119 966  72 852  62
sGC 461  52 1,033  144 909  99
sGC/NO 438  61 848  122 866  124
NO 432  111 903  162 854  141
Net hepatic lactate
balance, 	mol/kg/min
SAL 6.0  1.1 4.8  1.0 3.5  1.1
sGC 5.4  1.4 5.3  1.8 3.0  1.2
sGC/NO 4.9  0.9 8.0  2.6 6.3  1.9
NO 6.1  0.7 5.5  3.6 3.1  2.2
Arterial blood glycerol,
	mol/l
SAL 84  83 8  73 5  6
sGC 88  93 7  72 9  6
sGC/NO 74  14 29  73 1  8
NO 82  12 38  13 63  21
Net hepatic glycerol
uptake, 	mol/kg/min
SAL 1.2  0.2 0.4  0.1 0.5  0.1
sGC 1.8  0.2 0.5  0.2 0.6  0.2
sGC/NO 1.4  0.2 0.5  0.1 0.6  0.2
NO 1.4  0.3 0.6  0.4 1.1  0.5
Arterial plasma NEFA,
	mol/l
SAL 949  106 154  36 127  29
sGC 955  96 140  27 146  39
sGC/NO 883  161 101  21 121  33
NO 990  136 332  108 285  91
Net hepatic NEFA uptake,
	mol/kg/min
SAL 2.1  0.4 0.3  0.1 0.3  0.2
sGC 2.7  0.4 0.3  0.1 0.4  0.2
sGC/NO 2.1  0.4 0.3  0.1 0.4  0.2
NO 3.7  1.4 1.7  1.0 1.6  0.8
Data are means  SEM; n  10 in SAL and sGC groups. n  6i n
the sGC/NO group. n  3i nt h eNO group. All values in each
group during the experimental period are signiﬁcantly different (P 
0.05) from the basal period. Negative values for balance data indicate
net hepatic uptake.
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intraportal infusion of 8-Bromo cGMP inhibits NHGU in
the dog (31), thereby supporting the role of sGC in the
regulation of NHGU. Moreover, the dose of ODQ (0.8
	g/kg/min) that we used in the present study would have
produced ODQ levels markedly below those having been
shown to have off-target effects (100 	mol/l) in a 10C9 B
cell line (30). If we assume that all of the infused drug
accumulated in plasma (no binding or elimination), then
the level reached by the time NHGU was signiﬁcantly
increased (180 min) would have been 7 	mol/l. Since
some of the drug must have been cleared over the 90-min
infusion period, its plasma concentration was probably
closer to two orders of magnitude less than those shown
to have off-target effects (30).
There are several possible ways that hepatic NO/sGC/
cGMP could affect NHGU. Many of the biologic effects of
NO are mediated by PKG (32), so it is possible that a
PKG-dependent pathway produces the downstream signal
controlling NHGU. However, PKG levels in the liver are
very low, and very few hepatic metabolic enzymes have
been identiﬁed as physiologic targets of PKG (33,34). It has
also been well established that cAMP leads to activation of
cAMP-dependent protein kinase (PKA), which in turn
phosphorylates enzymes involved in the regulation of
glycogen metabolism, gluconeogenesis, and glycolysis
(35). Since cGMP inhibits PDE3, which hydrolyzes cAMP,
it is conceivable that inhibition of hepatic sGC could lower
hepatic cGMP, thereby removing the inhibition on PDE3,
which could, in turn, reduce hepatic cAMP levels and
potentially increase liver glucose uptake. However, the
PDE3 activity in the liver was not different following the
inhibition of sGC, suggesting that PDE3 was not responsi-
ble for the metabolic response seen in the present study. In
addition, we found that Akt phosphorylation was un-
changed in the liver in response to the change of hepatic
sGC/cGMP, suggesting that the regulation of NHGU by NO
is not likely caused by a modiﬁcation in the insulin-
signaling cascade.
It is also possible that NO/sGC/cGMP regulates NHGU
through the AMPK pathway. The phosphorylation and
activation of AMPK is catalyzed by upstream AMPK ki-
nases, such as LKB1 and calmodulin-dependent protein
kinase kinase (CaMKK), as well as allosteric activation via
AMP binding (36). NO may increase AMPK activity via
activation of AMPK kinases and/or inhibition of protein
phosphatases responsible for AMPK dephosphorylation
(37). It has recently been reported that NO can activate
AMPK in endothelium via a sGC/cGMP-dependent path-
TABLE 5
Postexperimental hepatic glycogen, glycogen synthase, and
phosphorylase activities, Akt, and GSK-3
 in conscious 42-h–
fasted dogs given saline or ODQ into the portal vein
Group
Value at the end of the
experiments
Terminal hepatic glycogen
content (mg/g liver)
SAL 23  3
sGC 34  2*
Hepatic glycogen synthase
activity ratio (L/H)
SAL 0.09  0.01
sGC 0.09  0.01
Hepatic glycogen phosphorylase
activity ratio (/ AMP)
SAL 0.12  0.02
sGC 0.12  0.01
Hepatic phospho Akt/total Akt
ratio
SAL 0.87  0.19
sGC 0.89  0.11
Hepatic phospho GSK-3
/total
GSK-3
 ratio
SAL 0.85  0.12
sGC 0.89  0.17
Data are means  SEM; n  10 in SAL and sGC groups. In the
presence of basal insulin, hepatic glycogen synthase activity ratio
(L/H) is 0.02, glycogen phosphorylase activity ratio (/ AMP) is
0.20, P-Akt/total Akt is 0.22 and P-GSK-3
/Total GSK-3
is 0.25.
*Signiﬁcant statistical difference (P  0.05) from the SAL group.
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FIG. 3. Phosphorylation of AMPK at Thr172 and ACC at Ser79 in the
liver biopsies at the end of the experiments. See Fig. 1A for a
description of study conditions. Data are means  SEM; *P < 0.05
compared with the SAL group. The blots shown are representative of 3
to 5 blots obtained from independent experiments.
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2 and subsequently
activating CaMKK (37,38). In snail muscle, 8-Bromo cGMP,
a cGMP analog, activates AMPK (39). In line with this
concept, in the present study, inhibition of hepatic sGC
was associated with a decrease (30%) in the phosphor-
ylation of Thr172 in hepatic AMPK with no change in its
protein level. This observation is conﬁrmed by a reduction
in the phosphorylation of ACC, a downstream marker of
AMPK activity, in the liver.
AMPK has been proposed to act as a “metabolic master
switch” mediating the adaptation to the cellular energy
status. It has also been implicated in the control of hepatic
glucose homeostasis (40), although the ﬁndings are not all
consistent. Bergeron et al. (41) showed that systemic
infusion of 5-aminoimidazole-4-carboxamide-1-
-D-ribo-
furanoside (AICAR), an AMPK activator, suppressed he-
patic glucose output in overnight-fasted normal and obese
rats. This ﬁnding was supported by the observation that a
constitutively active form of AMPK2 reduced glucose
output in cultured hepatocytes (42) and the in vivo obser-
vation that liver-speciﬁc AMPK2 KO mice had increased
fasting hepatic glucose production (43). These results
were in contrast, however, to those of Iglesias et al. (44)
who showed that an intraperitoneal injection of AICAR
caused a marked increment in net hepatic glycogen break-
down in 5-h–fasted rats. In agreement with this ﬁnding,
Camacho et al. (45) and Pencek et al. (46) showed that
intraportal AICAR infusion in 18-h–fasted conscious dogs
led to an increase in hepatic glucose output in the pres-
ence of basal glucagon, high physiologic insulin, and either
hyperglycemia, euglycemia, or hypoglycemia. These au-
thors also showed that the increase in hepatic glucose
output in response to AICAR infusion was caused by a
stimulation of hepatic glycogenolysis. The latter observa-
tion is in line with the suggestion that AMPK can inactivate
glycogen synthase and activate phosphorylase (47). Fur-
thermore, a recent observation showed that AMPK activa-
tion inhibited glucose phosphorylation and glucokinase
translocation in hepatocytes (48); therefore, inactivation
of AMPK in the liver could promote NHGU by augmenting
glucokinase translocation. Although the current study
shows that reductions in AMPK phosphorylation corre-
lated with reductions in hepatic cGMP levels, it remains to
be proven that AMPK is the link between enhanced NHGU
and sGC inhibition. Further studies in which AMPK is
activated or inhibited under hyperglycemic, hyperinsuline-
mic conditions will be needed to prove causality.
Although there was an 50% increase in hepatic glyco-
gen accumulation after the inhibition of sGC in the liver, it
is interesting to note that neither hepatic glycogen syn-
thase nor phosphorylase activities changed in response to
the inhibition of sGC. This is probably due to the fact that
the in vitro synthase and phosphorylase assays do not
reﬂect the allosteric regulation of the activities of these
enzymes which occurs in vivo and which may be enhanced
during sGC inhibition in the liver.
We previously showed that intraportal SIN-1 reduced
NHGU in the presence of portal glucose delivery, hyper-
glycemia, and hyperinsulinemia in conscious dogs (5).
Likewise, intraportal infusion of the NOS inhibitor L-
NAME enhanced NHGU under hyperinsulinemic hypergly-
cemic conditions in the absence of portal glucose delivery,
and this augmentation was partially reversed by giving
SIN-1 intraportally (6). In the present study, we found that
an increase in hepatic NO induced by SIN-1 infusion (NO
group) failed to reduce NHGU signiﬁcantly when the
portal glucose signal was absent, suggesting that an in-
crease in NO is not able to inhibit NHGU when hepatic
glucose uptake is not activated by a negative arterial portal
glucose gradient. The present results, combined with our
earlier ﬁndings, thus raise the possibility that the hepatic
NO/sGC/cGMP pathway produces a basal inhibitory signal
which limits NHGU during fasting. Further, we postulate
that the removal of this signal by feeding causes a de-
crease in NO, a decrease in hepatic cGMP, and an increase
in liver glucose uptake. Modulation of nitrergic signaling in
the liver may explain at least part of the effect of the portal
glucose signal on hepatic glucose uptake.
In conclusion, we demonstrate for the ﬁrst time that the
inhibition of sGC in the liver in vivo increases net hepatic
glucose uptake and hepatic glycogen synthesis under
hyperinsulinemic hyperglycemic conditions in conscious
42-h–fasted dogs. These data raised the possibility that the
NO/sGC/cGMP pathway is involved in the regulation of
liver glucose uptake during feeding, making it a potentially
useful target for the treatment of type 2 diabetes.
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